Damora Therapeutics (DMRA) Earnings Analysis
Damora Therapeutics (DMRA) has no confirmed upcoming earnings date. Last quarter (2026-03-18) it missed with EPS -3.24289 USD vs -0.14 USD est (-2216.3%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -0.17.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DMRA next report earnings?
No confirmed upcoming earnings date is currently scheduled for DMRA. This page updates as the calendar is published.
DMRA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-18 | -3.24289 USD | -0.14 USD | -2216.3% | Miss |
| 2025-05-08 | -1.92 USD | n/a | n/a | n/a |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
DMRA valuation and analyst view
| Trailing P/E | -0.17 |
|---|---|
| Trailing EPS | -177.15305 USD |
| Price / book | 0.08 |
| Dividend yield | 0.00% |
| Market cap | 1.84B |
| Analyst consensus | Buy (3 buy / 0 hold / 0 sell) |
| Avg price target | 40 USD |
Related research pages
Frequently asked questions
When is Damora Therapeutics (DMRA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for DMRA. This page updates as the calendar is published.
Did DMRA beat earnings last quarter?
In its 2026-03-18 report, DMRA posted EPS of -3.24289 USD versus a -0.14 USD estimate — a miss of 2216.3%.
What is DMRA's earnings track record?
Over the last 1 reported quarters with consensus data, DMRA beat estimates 0 times (0%).
What is DMRA's current P/E ratio and EPS?
DMRA trades at a trailing P/E of -0.17 on trailing EPS of -177.15304523830875 USD.
What do analysts rate DMRA?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 40 USD.